Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
---|---|---|---|
USD 1,434.80 Million | USD 2,615.60 Million | 6.90% | 2023 |
The global mice model market size was worth around USD 1,434.80 million in 2023 and is predicted to grow to around USD 2,615.60 million by 2032 with a compound annual growth rate (CAGR) of roughly 6.90% between 2024 and 2032.
Mice model refers to a group of laboratory mice that are used for conducting research and analysis to study certain aspects of human health, diseases, and physiology. Although there are several model organisms that can be used for such applications, mice model is preferred since certain mammalian features in humans are shared with mice. In addition to this, mice are also known to suffer from several diseases that affect humans.
According to market research, a significantly large number and types of mouse models have been created worldwide for targeting specific medical conditions affecting human health using methods such as genetic engineering and selective breeding.
One of the other main reasons for the preference for mouse models over other counterparts is that around 80% of human genetic components can be found in mice. The surge in the number of medical researchers who are seeking to learn more about existing medical conditions without cures, such as cancer and human immunodeficiency virus (HIV), is projected to help create demand for mice models.
Furthermore, the growing introduction of novel ways of creating a more efficient batch of mice modes may further help the industry thrive during the forecast period. One of the major factors impacting the overall revenue in the industry is the concern and questions over ethical stature or the process due to aspects of animal cruelty being associated with the use of mice models.
Increasing cancer research to create demand in the industry during the forecast period
The global mice model market is projected to grow due to the increasing number of cancer research worldwide. According to market analysis, cancer is a leading cause of medically-induced deaths worldwide. The World Health Organization (WHO) estimates that nearly 10 million deaths occurred in 2022 due to cancer. It is also one of the most widely prevalent medical conditions impacting the lives of patients and their families worldwide. The world has reached an urgent state of developing cures or effective treatments for cancer due to the burgeoning pressure on the global healthcare infrastructure. In addition to this, affordable cancer cures and treatments are a necessity in middle and low-income economies, which further drives the demand for mice models.
In October 2024, researchers from the Josep Carreras Leukaemia Research Institute developed a novel mouse model for studying several aspects of cancer immunotherapy. According to the researchers, the immune system of the body cannot be replicated in a computer simulation. Animal testing continues to remain a preferred method of learning the ways in which the immune system reacts to cancer.
The current methods are inefficient since they have a high risk of developing graft-versus-host disease, which can be life-threatening in mice models. To mitigate these challenges, the researchers have developed a new mouse model leveraging human cord blood mononuclear cells. The model has already shown an improved ability to not only produce but also sustain a balanced immune cell population.
Growing investments in medical research will generate significant revenue in the industry
Due to the increasing pressure on the global healthcare architecture, governments worldwide, along with private institutes, have launched new programs to support the development of medical research facilities worldwide. These units are equipped with all essential tools required to conduct research and analysis for diseases along with developing new drugs and treatments. The global mice model market can benefit in the long run with the construction of new research facilities.
In May 2024, the School of Medicine of Emory University announced the launch of a new center for novel medicines. The university aims to develop and amplify drug development of medicines that can save lives. The Center for New Medicines (CNM) will be powered using advanced technologies, resources, and infrastructure to support the university’s mission.
Ethical concerns over the use of animals for research and drug testing will limit the industry’s growth rate
The global industry for mice model is expected to be restricted due to the ethical concerns associated with the use of animals for conducting studies, research, and testing new drugs. For instance, several cultures and religions are against animal cruelty, and the mice model can be considered a form of cruelty against living organisms.
Furthermore, animal welfare organizations such as People for the Ethical Treatment of Animals (PETA) and others have urged for developing alternatives to the mice model when developing new medicines or for research purposes.
Rising introduction of new models to generate expansion possibilities in the future
The global mice model market is projected to generate growth opportunities due to the rising introduction of new models offering improved results. For instance, in July 2024, researchers at the University of Texas Health Science Center announced the development of a new humanized mouse model. It has a human immune system and hence offers improved accuracy in terms of final results. The human-like gut microbiome is capable of amplifying specific antibody responses.
According to the researchers, the model is created to outperform the limitations of currently available in vivo human models. The mouse model known as TruHuX consists of a fully functional human immune system, including germinal centers, lymph nodes, human T and B lymphocytes, thymus human epithelial cells, plasma cells, and memory B lymphocytes.
In September 2023, Biocytogen Pharmaceuticals Co., Ltd. launched the RenMice® series. It consists of comprehensive solutions, including independently developed TCR mice and fully human antibody mice. RenMice® series is made using proprietary intellectual property. One of the key applications of the novel introduction includes the discovery of bispecific antibodies, fully human monoclonal antibodies, nanobodies, bispecific antibody-drug conjugates (BsADCs), TCR-mimic antibodies, and fully human T-cell receptors (TCRs).
Biological limitations will challenge the market expansion rate in the future
The global mice model industry is projected to be challenged by the biological limitations of the animal-dependent model. Market research suggests that mice may not mimic all aspects of human diseases and physiology. The results thus obtained may not deliver optimal results. The ongoing innovation in terms of alternate and more accurate technologies will limit further market expansion.
Report Attributes | Report Details |
---|---|
Report Name | Mice Model Market |
Market Size in 2023 | USD 1,434.80 Million |
Market Forecast in 2032 | USD 2,615.60 Million |
Growth Rate | CAGR of 6.90% |
Number of Pages | 227 |
Key Companies Covered | Cyagen Biosciences, Charles River Laboratories, Ozgene, The Jackson Laboratory, Labcorp Drug Development, Taconic Biosciences, Champions Oncology, Horizon Discovery, Envigo, Harbor BioMed, Pharmaron, GenOway, Biocytogen, Crown Bioscience, Trans Genic Inc., and others. |
Segments Covered | By Technology, By Mice, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2023 |
Historical Year | 2018 to 2022 |
Forecast Year | 2024 - 2032 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
The global mice model market is segmented based on technology, mice, and region.
Based on the technology, the global market segments are nuclear transfer, embryonic stem cell injection, microinjection, CRISPR, and others. In 2023, the highest demand was listed in the CRISPR segment. According to market analysis, CRISPR-Cas9 is a novel and highly advanced gene-editing technology that facilitates modification of the Deoxyribonucleic Acid (DNA) of an organism. It is highly precise and accurate in terms of result. In 2023, the segment controlled over 34.05% of the final revenue.
Based on the mice, the global market divisions are hybrid, knockout, outbred, inbred, and others. In 2023, the highest demand was listed in the inbred segment. These strains are produced after 20 generations of mating between brother-sisters of mice. This further results in the development of animal strains that are genetically similar in all aspects. During the forecast period, the outbred segment is likely to generate the highest revenue.
North America to generate the highest revenue during the forecast period
The global mice model market is expected to be led by North America during the forecast period. The region dominated nearly 81.0% of the global revenue in 2023. The surge in the prevalence of several life-threatening medical conditions, including cardiovascular diseases (CVDs), cancer, diabetes, and viral diseases, will fuel demand for mice models in the region.
Furthermore, North American revenue is heavily influenced by the presence of a research-intensive healthcare industry. Countries such as the US and Canada spend heavily on medical research, resulting in greater demand and application for genetically engineered mouse models.
In October 2024, researchers at the La Jolla Institute for Immunology (LJI) in the US announced the introduction of six lines of humanized mice. According to the scientists, the mice can serve as ideal models for studying COVID-19. The cells of the mice were engineered to include two molecules that are associated with SARS-CoV-2 infection of human cells. According to official claims, the mice have helped the researchers learn about the impact of the virus on human health.
The global mice model market is led by players like:
The global mice model market is segmented as follows:
By Technology
By Mice
By Region
FrequentlyAsked Questions
Mice model refers to a group of laboratory mice that are used for conducting research and analysis to study certain aspects of human health, diseases, and physiology.
The global mice model market is projected to grow due to the increasing number of cancer research worldwide.
According to study, the global mice model market size was worth around USD 1,434.80 million in 2023 and is predicted to grow to around USD 2,615.60 million by 2032
The CAGR value of the mice model market is expected to be around 6.90% during 2024-2032.
The global mice model market is expected to be led by North America during the forecast period.
The global mice model market is led by players like Cyagen Biosciences, Charles River Laboratories, Ozgene, The Jackson Laboratory, Labcorp Drug Development, Taconic Biosciences, Champions Oncology, Horizon Discovery, Envigo, Harbor BioMed, Pharmaron, GenOway, Biocytogen, Crown Bioscience and Trans Genic Inc.
The report explores crucial aspects of the mice model market including detailed discussion of existing growth factors and restraints while also browsing future growth opportunities and challenges that impact the market.
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed